Novel VHL-Recruiting PROTACs Degrade Mutant EGFR and Show Efficacy in NSCLC Models
- Researchers designed VHL-recruiting PROTAC degraders targeting EGFR, aiming to overcome acquired resistance to conventional EGFR kinase inhibitors in non-small cell lung cancer (NSCLC).
- Lead compounds C4 and D4 achieved potent, selective, and durable degradation of the EGFR Del19 and L858R resistance mutants.
- C4 induced cell cycle arrest and apoptosis, showed subnanomolar antiproliferative activity, and produced significant tumor regression in an HCC827 xenograft model at low intravenous doses on a reduced twice-weekly schedule.
- D4 was orally bioavailable and blood-brain barrier penetrant, and oral dosing completely halted tumor growth in vivo.
- The findings support a degradation-based strategy, rather than conventional inhibition, as a route to next-generation EGFR-directed therapies with potential central nervous system relevance.
D4 clearing both the oral bioavailability and blood-brain-barrier bars is the real headline here, more than the VHL-EGFR chemistry itself — most VHL degraders are 800-1000 Da PEG-linked bricks, gorgeous in a dish, DOA as an oral CNS drug. That's the developability wall this class has been stuck at. C4's profile reads more like a conventional IV PROTAC: subnanomolar antiproliferative potency and regression at low twice-weekly doses is a solid therapeutic index, but the reduced dosing schedule signals they're still managing catalytic turnover and clearance, not solving it outright. Degrading Del19/L858R instead of inhibiting them sidesteps the secondary-mutation resistance that keeps eroding osimertinib responses. If selectivity holds against WT EGFR in vivo, this is a real next-gen chemotype for NSCLC, not just a mechanistic proof-of-concept.